


PRELIMINARY PROGRAM



**2009 Joint
Meeting of
the Society for
Neuro-Oncology and
the AANS/CNS
Section on Tumors**

**October 22-24, 2009
at the Hilton New Orleans Riverside
New Orleans, Louisiana**



American
Association of
Neurological
Surgeons



www.cns.org/snosot

Dear Colleague:

On behalf of the Society for Neuro-Oncology (SNO) and the AANS/CNS Section on Tumors, we invite you to join us in New Orleans, Louisiana for the 2009 Joint Meeting. These leading organizations are joining scientific research efforts for the first time ever to present the latest developments in neuro-oncology and tumor surgery.

This robust and dynamic educational event is truly a first of its kind that offers the most comprehensive review of cutting-edge laboratory and clinical research in the field of neuro-oncology and tumors. Through the collaborative efforts of our two societies, we have assembled an outstanding scientific program. The Thursday morning Education Half-Day session offers attendees two options: *Personalized Medicine: Is it the Future or Now?* and *Enhancing Quality of Life throughout the Illness Trajectory*, while leading experts address topics ranging from stem cell research and genomics to immunotherapy and surgical therapies during our Friday and Saturday morning Sunrise Sessions.

Over 575 oral and poster abstracts will be presented during our daily Scientific Sessions and our Thursday and Friday evening poster receptions and discussion. And don't forget to visit the exhibit hall, showcasing the latest technological advances in neuro-oncology and tumor surgery.

The Society for Neuro-Oncology (SNO) and the AANS/CNS Section on Tumors are also pleased to announce their alliance with the Congress of Neurological Surgeons and hope that you will extend your stay in New Orleans to take advantage of the many neuro-oncology and tumor-focused sessions being offered at the 2009 CNS Annual Meeting, October 24-29. Through this partnership, the three organizations are bringing renewed focus to neuro-oncology and tumor research.

So make your arrangements today and join us for this groundbreaking scientific meeting. We look forward to welcoming you to New Orleans!

Sincerely,

Randy Jensen M.D. Ph.D.

Randy L. Jensen, MD, PhD
Scientific Program Co-Chair

Frederick F. Lang, MD

Frederick F. Lang, MD
Scientific Program Co-Chair

Meeting Overview

The Society for Neuro-Oncology (SNO) and the AANS/CNS Section on Tumors are coming together for the first time to present the latest developments in neuro-oncology and tumor surgery. Expect the year's most comprehensive review of cutting-edge laboratory and clinical research in the field of neuro-oncology and tumors at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors being held October 22–24, 2009 in New Orleans, Louisiana. The meeting will take place at the Hilton New Orleans Riverside Hotel, where you'll be just steps from the famed Riverwalk Marketplace.



The Hilton New Orleans Riverside Hotel is the official Meeting Headquarter Hotel 2 Poydras Street

Presiding over the mighty Mississippi, the Hilton New Orleans Riverside is located a short distance from the French Quarter. This full-service luxury complex offers excellent service and an array of services for your convenience and comfort.

Who Should Attend

The 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors Meeting is designed for neurosurgeons, neuro-oncologists, medical oncologists, neuropathologists, radiation oncologists, neuroradiologists, pediatricians, laboratory scientists, residents, nurses, physician assistants and other specialists involved in the research, diagnosis, care and treatment of intracranial, central nervous system and spinal tumors.

Educational Objectives

Abstracts have been chosen on the basis of their research merit and their conformation with the following educational objectives for this meeting. After attending conference sessions, participants should be able to achieve these objectives:

- Summarize current studies on epidemiologic factors associated with central nervous system tumors.
- Describe the impact of brain tumors and their treatments on patients, quality of life, and neurocognitive intervention strategies.
- Discuss new research on cell biology, signal transduction inhibition strategies, and factors associated with angiogenesis and invasion in brain tumors.
- Summarize new research on genes that are associated with brain tumors and related therapeutic strategies.
- Discuss new research on CNS anti-tumor immunoreactivity.
- Describe advances in imaging and neuropathology as they relate to diagnosis, prognosis, and response to therapy for patients with CNS tumors.
- Discuss advances in pharmacology, experimental therapeutics, and radiobiology that may improve future therapies for patients with CNS tumors.
- Compare results of new clinical studies for CNS tumors.
- Summarize quality of life or symptom management initiatives beneficial to brain tumor patients.

Accreditation/CME Credit Designation

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Congress of Neurological Surgeons, the Society for Neuro-Oncology and the AANS/CNS Section on Tumors. The Congress of Neurological Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Congress of Neurological Surgeons designates this educational activity for a maximum of 21.25 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity. An additional four (4) *AMA PRA Category 1 Credits™* can be earned by attending the Education Half Day.

Meeting Location

We invite you to join us in the extraordinary city of New Orleans. This city at the mouth of the Mississippi River is one of America's treasures – with a distinct history, culture and identity all its own. Come experience this city for yourself – enjoy jazz in its most pure form, southern hospitality that reflects a time gone by, and of course, culinary delights blended from the many cultures that call New Orleans home. We hope you enjoy your stay as you explore this city and *laissez les bons temps rouler!*

Exhibit Products & Services

Your preferred exhibitors encourage you to stop by their booths for one-on-one discussions, hands-on product demonstrations or to catch a glimpse of the many exciting new products and services available for show at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors.

Exhibit Hours

The Exhibit Hall will be located in the Hilton New Orleans Riverside.

Thursday, October 22
8:00 AM – 7:15 PM

Friday, October 23
8:00 AM – 7:15 PM

Saturday, October 24
8:00 AM – 12:00 PM

List of Exhibitors

Accuray, Inc.
Ark Therapeutics Ltd.
Baxter
BrainLAB
Castle Biosciences, Inc.
CERN Foundation
CNSVital Signs
Elliquence, LLC
Enzon Pharmaceuticals, Inc.
Genentech, Inc.
LabCorp
Lippincott Williams & Wilkins
Medtronic, Inc.
NICO Corporation
Schering-Plough Pharmaceuticals
US Radiosurgery

Special Thanks to Our Corporate Supporters!

Bristol Myers Squibb
CERN Foundation
Schering Plough Pharmaceuticals

As of July 22, 2009

Registration & Housing Information

The deadline for advance registration and housing is September 23, 2009.

For your convenience, you can register, reserve your hotel room and more via these three methods:

Online: www.cns.org/snosot
Internet booking is available 24 hours a day, seven days a week.
Credit card only.
Receive immediate Registration and Housing e-mailed Confirmation Notification.

Fax: 703 502 0257
Credit card only.
Allow seven business days for Registration and Housing e-mailed Confirmation Notification.

Mail:
SNO/SOT Registration Center
11208 Waples Mill Road, Suite 112
Fairfax, VA 22030
Credit card or check (no wire transfers)
Allow seven business days for Registration and Housing e-mailed Confirmation Notification.

Payment by Check
Checks must be payable in US dollars and drawn on a US bank. Make checks payable to:
SNO/SOT Registration Center.
Include \$250 per room hotel deposit plus appropriate fees for registration and any optional items purchased.

Registration Cancellation/Refunds
Full registration refunds, less a \$100 processing fee, will be granted if written requests for cancellation are received by September 30. No refunds of any kind will be given after this date, regardless of cause. Refunds will not be given for no-shows. Written requests may be e-mailed to snosot@jsparko.com, faxed to

703 502 0257 or mailed to 11208 Waples Mill Rd, Suite 112, Fairfax, VA 22030.

Important Dates To Remember

September 23
Advance Registration Discount and Housing Deadline.

September 30 Cancellation Deadline

- \$100 Processing fee will be charged for written cancellation requests received during this time.
- No refunds given after this date.

September 30 at 11:00 AM EST
Any changes to hotel reservations must be made directly with hotel from this date on.

What's Included in the Registration Fee?

Meeting Only Registration includes the following:

- Daily Continental Breakfast.
- Daily Beverage Breaks.
- Daily Scientific Content.
- Entrance to the Exhibit Hall.
- One ticket to the Friday Reception.

Education Day Only Registration includes the following:

- Thursday Continental Breakfast.
- Thursday Beverage Breaks.
- Morning Sessions on Thursday, October 22.

Full Meeting Registration includes both Education Day and Meeting Only content.

Spouse/Guest Registration (Over 13 years of age.) includes the following:

- Daily Continental Breakfasts with Medical Attendees.
- One ticket to the Friday Reception.

Child Registration

Although there is no registration fee, children under 13 years of age should register for the Joint Meeting to receive a badge. Registered children may take part in the daily continental breakfast.

Children under the age of 18 are not allowed on the exhibit floor.

Special Rates!

The Society for Neuro-Oncology and the AANS/CNS Section on Tumors is proud to announce its alliance with the 2009 CNS Annual Meeting. We encourage you to make plans to attend the:

2009 CNS Annual Meeting
October 24-29
Ernest N. Morial Convention Center,
New Orleans, Louisiana

The CNS has lined up several new courses and lectures that may be of interest to neuro-oncology specialists.

Save up to 25% on combined registration fees when you register for both meetings prior to September 23!*

Members of the SNO/Section on Tumors register for the Joint Meeting for \$225.

Non-Members register for the Joint Meeting for \$415.

Residents/Trainees register for the Joint Meeting for \$50.

Nursing/Allied Health personnel register for the Joint Meeting for \$115.

Special registration rates for the CNS Annual Meeting are also available.

*In order to receive the special registration fees, you must register for the 2009 CNS Annual Meeting **within three days** of registering for the 2009 Joint Meeting of the Society

for Neuro-Oncology and the AANS/CNS Section on Tumors.

Hotel Reservations

Presiding over the mighty Mississippi, the Hilton New Orleans Riverside is located adjacent to the Riverwalk Marketplace and a short distance from the French Quarter. This full-service luxury complex offers excellent service and an array of services for your convenience and comfort.

- Concierge services.
- Fitness center – Complimentary Access for Joint Meeting Attendees.
- Gift shop.
- Business center.
- 2 Pools.
- High-speed internet.
- Restaurant.
- Room service.

Hotel Cancellation or Change Policy

Prior to September 30, 2009 at 11:00 AM, EST – Changes are subject to availability and cancellations may be made online at www.cns.org/snosot or via e-mail at snosot@jspargo.com.

After September 30, 2009 at 11:00 AM, EST to 72 Hours Prior to Your Scheduled Arrival Date – Please contact the Hilton directly with all changes or cancellations. The hotel will retain the \$250 hotel deposit for cancellations not made at least 72 hours prior to your confirmed arrival date. This cancellation policy is strictly enforced and no exceptions will be made. Please retain the cancellation confirmation from the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors Registration and Housing Center. The cancellation number provided to you by the hotel as proof of cancellation will be required to resolve any disputes.

Americans with Disabilities Act/Special Needs and Requests

The 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors wishes to take the necessary steps to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently than other individuals because of the absence of auxiliary aids and services.

If you require any of the auxiliary aids or services identified in the Americans with Disabilities Act in order to attend any 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors programs, or have any special needs requests, such as food allergies, please contact the SNO/SOT Registration Center at snosot@jspargo.com. Please provide any requests at least 30 days prior to the Meeting to guarantee accommodation.

Scooter and wheelchair rentals are available by contacting Scootaround Inc. at their toll-free hotline: 888 441 7575. You can also submit a rental inquiry on the web at www.scootaround.com.

On-site Registration Hours

Pick up your registration packet at the Hilton during the following times:

Thursday, October 22
7:00 AM – 6:00 PM

Friday, October 23
6:00 AM – 6:00 PM

Saturday, October 24
6:00 AM – 12:00 Noon

8:00 AM – 12:00 PM

PERSONALIZED MEDICINE: IS IT THE FUTURE OR NOW?

8:00 AM **Introduction**
Randy L. Jensen, Frederick F. Lang

PATHOLOGY

8:15 AM **Predictive and Prognostic Value of Global Profiling Technologies in Neuropathology**
Kenneth D. Aldape

8:35 AM **Predictive and Prognostic Value of Specific Molecular Biomarkers in Neuropathology**
Daniel J. Brat

8:55 AM **Discussion**

SURGERY

9:05 AM **Technology Supporting Personalized Surgical Care**
Christopher Nimsy

9:25 AM **Clinical Decision-making in Surgery Incorporating Molecular Markers**
Cameron Brennan

9:45 AM **Discussion**

9:55 AM **Coffee Break**

RADIATION

10:10 AM **Technology Supporting Personalized Radiation Oncology**
Christina Tsien

10:30 AM **Role of Molecular Markers in Clinical Decision-making in Radiation Oncology**
Minesh P. Mehta

10:50 AM **Discussion**

MEDICINE

11:05 AM **Molecular Markers for Guiding Decision-making in Personalized Neuro-oncology**
Timothy F. Cloughesy

11:25 AM **Molecular Markers for Guiding Development of Clinical Trials of Personalized Neuro-oncology**
Mark R. Gilbert

11:45 AM **Discussion**

8:15 AM – 12:00 PM

SPECIAL CONCURRENT SESSION ON ENHANCING QUALITY OF LIFE THROUGHOUT THE ILLNESS TRAJECTORY

8:15 AM **Introduction to the Meeting**

8:20 AM **Panel/Patient Presentation**

8:45 AM **Good News or Bad: Communicating with Your Patient**
Walter F. Baile

9:15 AM **Chemobrain? Impact of Tumor and Treatment on Neurocognitive Function: What We Know, Where to Go**
Jeffrey Wefel

Quality of Life ... (Continued)

- 9:45 AM** **Question/Answers with Presenters**
- 10:00 AM** **Coffee Break**
- 10:15 AM** **Radiation of Brain Metastases, Toxicity and Interventional Trials**
Paul D. Brown
- 10:45 AM** **The Other Health Care Professional: Training the Caregiver**
Harriet Patterson
- 11:15 AM** **Promoting Comfort and Choice at the End of Life**
Sherry W. Fox
- 11:45 AM** **Question/Answers with Presenters**
- 12:00 – 1:00 PM** **Lunch**

Thursday, October 22

JOINT MEETING OF THE SOCIETY FOR NEURO-ONCOLOGY AND THE AANS/CNS SECTION ON TUMORS

- 1:00 PM** **Introduction**
Randy L. Jensen, Frederick F. Lang

Top Scoring Abstracts

Moderators: Susan Chang, Michael McDermott

- | | | |
|----------------|------------|--|
| 1:15 PM | 433 | Adjuvant Whole Brain Radiotherapy versus Observation after Radiosurgery or Surgical Resection of 1–3 Cerebral Metastases: Results of the EORTC 22952–26001 Study
Riccardo Soffietti, Italy |
| 1:30 PM | 109 | Human Bone Marrow Derived Mesenchymal Stromal Cells Expressing S–Trail: A Cellular Delivery Vehicle for Human Glioma Therapy
Lata G. Menon, United States |
| 1:45 PM | 131 | Chromatin Remodeling–mediated Overexpression of MGMT as a Novel Mechanism of Temozolomide Resistant in Glioblastoma Xenografts
Gaspar J. Kitange, United States |
| 2:00 PM | 133 | CDK4/6 Small Molecule Inhibitor PD–0332991 Acts in Combination with Radiation Therapy to Significantly Extend the Survival of Mice with Intracranial Glioblastoma Xenografts
Karine Michaud, United States |
| 2:15 PM | 142 | Sunitinib Inhibits Glioma Growth by Blocking Progenitor Cell Recruitment
Aaron M. Tannenbaum, United States |
| 2:30 PM | 249 | Six–month Progression–free Survival as an Alternative Primary Efficacy Endpoint to Overall Survival in Newly–diagnosed Glioblastoma Patients Receiving Temozolomide
Mei–Yin C. Polley, United States |
| 2:45 PM | 545 | Treatment of Primary High–grade Glioma with Sitimagene Ceradenovec (Cerepro®) and Ganciclovir Gene Medicine: Update of Phase III Results
Zvi Ram, Israel |
| 3:00 PM | 557 | Hot–spot Areas in FET–PET Delineate Malignant Tumor Parts within Suspected WHO Grade II Glioma
Joerg–Christian Tonn, Germany |
| 3:15 PM | | Refreshment Break |

Thursday, October 22

Plenary Session I: Tumor Biology

Moderators: Russell O. Pieper, Donald M. O'Rourke

3:30 PM	37	MicroRNA Alterations in Glioblastoma; Effects on Proliferation, Migration, Metabolism and Self-renewal Sean Lawler, United States
3:40 PM	4	Targeting Myosin II Activity Blocks Glioma Invasion Even in the Presence of Multiple Motogenic Signals Steven Rosenfeld, United States
3:50 PM	12	IGFBP2 Is a Candidate Biomarker for INK4A-ARF Status and a Therapeutic Target for High-grade Gliomas Lynette Moore, United States
4:00 PM	40	Adenovirus-induced Autophagy Requires Expression of Stress-related Kinases but No Downregulation of AKT Juan Fueyo, United States
4:10 PM	32	Mutant EGFR Signaling in Glioblastoma Maintenance and the Emergence of EGFR-Independent Tumor Growth-promoting Mechanisms Jill Wykosky, United States
4:20 PM	26	RTVP-1 Regulates Glioma Cell Spreading and Migration via Interaction with N-Wasp Chaya Brodie, United States
4:30 PM	43	The Role of ILK and NFκ B in the IGFBP2 Pathway Kristen M. Holmes, United States
4:40 PM	46	IKBA is an EGFR-Regulating Tumor Suppressor in Glioblastoma Markus Bredel, United States
4:50 PM	61	CD44 Loss of Function in Spontaneous Murine Glioma Implicates CD44 in Tumor Maintenance Stacy Decker, United States
5:15 PM		Poster Viewing and Reception
6:15 – 7:15 PM		Poster Discussion

7:30 – 9:30 PM

SATELLITE SYMPOSIA

Case-based Discussion of Emerging Evidence: Tailoring Therapy for Patients with High-Grade Gliomas	Supported by Schering Plough
The Future Treatment of High Grade Glioma	Supported by Ark Therapeutics
Expanding Glioblastoma Treatment with Targeted Integrin Inhibition	Supported by EMD Sorono

Friday, October 23

7:00 – 8:00 AM

SUNRISE SESSIONS – MEET THE EXPERTS

Neurosurgical Oncological Endoscopy	Leader: Theodore H. Schwartz
Meningiomas: Current Basic Science and Clinical Treatments	Leader: Michael William McDermott
Cancer Stem Cell: State of the Hypothesis	Leader: Lawrence D. Recht
Metastatic Spine Tumors: Biology and Therapy	Leader: Laurence D. Rhines

8:00 AM – 12:00 PM

MORNING PLENARY SESSION

8:00 AM	Introduction of Farber Award Winner: Peter B. Dirks Susan Chang
8:10 AM	Farber Lecture Peter B. Dirks

Plenary Session II: Medical Therapies

Moderator: Jeffrey N. Bruce, Mark R. Gilbert

8:30 AM	283	International Retrospective Study of 1000+ Adults with Anaplastic Oligodendroglial Tumors Andrew B. Lassman, United States
8:40 AM	99	Mesenchymal Stem Cells Display Tumor Specific Tropism in a Spontaneous Brain Tumor Model Tiffany A. Doucette, United States
8:50 AM	117	Human Glioblastoma Stem Cells Targeted through Treatment with Temozolomide and Gamma-Secretase Inhibitors Alonzo H. Ross, United States
9:00 AM	144	Effects of the RTOG 0525 Dose-Intense Temozolomide Schedule on GBM MGMT Activity and Overall Survival in an Orthotopic Xenograft Model Cliff Robinson, United States
9:10 AM	38	Identification of Novel Targets in GBM Using Hi-throughput siRNA Kinome Array Screening Deepti Ramnarian, United States
9:20 AM	248	Phase II and Pharmacogenomics (PGX) Study of Enzastaurin (ENZ) plus Temozolomide (TMZ) and Radiation Therapy (RT) in Patients with Glioblastoma Multiforme (GBM) or Gliosarcoma (GS) Nicholas A. Butowski, United States
9:30 AM	297	Updated Results of Phase II Trial of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme Albert Lai, United States
9:40 AM	112	Glioma Therapy Using Second Generation HIF-activated Adenoviruses with Improved Replication, Oncolytic and Anti-tumor Efficacy Dawn E. Post, United States
9:50 AM	152	Human Schwannomas Express Activated Platelet-derived Growth Factor Receptors and CKIT and Are Growth Inhibited by Gleevec (Imatinib Mesylate) Abhijit Guha, Canada
10:00 AM	155	A Potential New Therapeutic Agent: CCN3 Can Suppress Glioma Growth through Inhibition of Notch Signal Transduction Kartik Krishnan, United States
10:15 AM		Coffee Break
10:30 AM		Introduction of Keynote Speaker: Raymond Sawaya Frederick F. Lang
10:35 AM		Keynote Speaker Raymond Sawaya

Plenary Session III: Surgical Therapies

Moderators: Ronald E. Warnick, Randy L. Jensen

11:00 AM	566	Phase II Prospective Trial of Stereotactic Radiosurgery following Surgical Resection for Brain Metastases: Predictors of Local Control Cameron Brennan, United States
11:10 AM	592	Time-resolved Fluorescence Spectroscopy for Intra-operative Delineation of Human Gliomas Pramod Butte, United States
11:20 AM	539	The Outcome of Initial Radiological and Clinical Surveillance in Vestibular Schwannoma: A Prospective Cohort Study in a Single Centre Sarah R. Eljamel, United Kingdom

11:30 AM	558	Assessment of the Peritumoral Micro-environment following Craniotomy Using Intracerebral Microdialysis Behnam Badie, United States
11:40 AM	567	Impact of Stereotactic Radiosurgery Treatment on Survival Time of Breast Cancer Patients with Neurologically Asymptomatic Parenchymal Brain Metastases Zhiyuan Xu, United States
11:50 AM	527	Trial to Survive: The Impact of Enrollment in Clinical Trials on Survival of Patients with GBM Tal Shahar, Israel
12:00 PM	543	Adult Intracranial Ependymomas: Long-term Outcome and Prognostic Factors Analysis in a Retrospective Series of 114 WHO Grade II Patients Philippe Metellus, France
12:15 – 1:15 PM		Lunch

1:15 – 3:00 PM Afternoon Concurrent Sessions

EXPERIMENTAL AND CLINICAL THERAPIES (Concurrent Session I)

Moderators: Patrick Wen, Timothy F. Cloughesy

1:15 PM	127	MPC-6827: Anti-tumor Activity in an Orthotopic Brain Model and in Combination with Bevacizumab Margaret K. Yu, United States
1:25 PM	129	Inhibition of PI3K/MTOR Pathways in Glioblastoma and Implications for Combination Therapy with Erlotinib, Temozolomide, and Radiation Gautam Prasad, United States
1:35 PM	123	IL13 Conjugated Liposomal Doxorubicin as a Therapeutic Agent for High-grade Astrocytomas A.B. Madhankumar, United States
1:45 PM	119	Combined Anti-VEGF and Radiotherapy for Metastatic Brain Melanoma Ilya G. Lim, United States
1:55 PM	255	Proposal for an Updated Response Criteria in Malignant Gliomas Patrick Y. Wen, United States
2:05 PM	247	High Dose Methotrexate and Rituximab with Deferred Radiotherapy for Newly Diagnosed Primary CNS Lymphoma Marc C. Chamberlain, United States
2:15 PM	253	New Therapeutic Approach for Brain Tumors: Intranasal Administration of Ras Inhibitor Monoterpene Perillyl Alcohol Clovis O. Fonseca, Brazil
2:25 PM	305	Bevacizumab (BV) in Combination to Temozolomide (TMZ) and Radiation Therapy (RT) Followed by BV, TMZ and Irinotecan (CPT-11) for Newly Diagnosed Glioblastoma Multiforme (GBM): A Phase 2 Trial Annick Desjardins, United States
2:35 PM	270	Patterns of Progression in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab Alone or in Combination with Irinotecan in the Brain Study Whitney B. Pope, United States

EPIDEMIOLOGY AND QUALITY OF LIFE (Concurrent Session II)

Moderators: Elizabeth Claus, Jeffrey Wefel

1:15 PM	388	Palliative Home Care for Brain Tumor Patients: Results and Cost/Utility Analysis of 6 Years of a Pilot Project Andrea Pace, Italy
1:25 PM	411	Early Surgical Intervention in 1,089 Adult Ganglioglioma Patients Is Associated with Improved Clinical Seizure Outcomes Isaac Yang, United States

Friday, October 23

1:35 PM	386	Patient and Caregiver Congruence in Symptom Report and Association with Patient Neurocognitive Status Terri S. Armstrong, United States
1:45 PM	342	Understanding the Molecular Bases of Chemotherapy-Induced Cognitive Impairment: Normal Neural Precursors Have Differential Sensitivity to Commonly Used Chemotherapy Drugs Daniela A. Bota, United States
1:55 PM	338	Neurocognitive Function in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab Alone or in Combination with Irinotecan in the Brain Study Jeffrey S. Wefel, United States
2:05 PM	344	Neurocognitive Outcome 12 Months following Cerebellar Mutism Syndrome (CMS) in Pediatric Patients with Embryonal Tumors: Results of a Prospective Study with Matched Controls Shawna L. Palmer, United States
2:15 PM	91	High Mobility Group-A2 (HMGA2) Gene Polymorphism Is Associated with Long-term Survival in Glioblastoma Yanhong Liu, United States
2:25 PM	92	A Novel Approach To Exploring Potential Pairwise Interactions among Single-Nucleotide Polymorphisms of Inflammation-Related Genes in Gliomagenesis: An Exploratory Case-only Study Michael E. Scheurer, United States
2:35 PM	83	Evaluation of Concomitant Temozolomide and Radiotherapy Treatment in Patients with Glioblastoma Multiforme in Two Canadian Tertiary Care Centers Ibrahim Mohammed Alnaami, Canada

RADIOLOGY (Concurrent Session III)

Moderators: Sarah C. Jost, Tracy Batchelor

1:15 PM	468	Predicting MGMT Gene Promoter Methylation Status of Glioblastomas Using MRI Texture Paula de Robles, Canada
1:25 PM	488	Imaging and Biologic Correlates in Phase II Study of Bevacizumab (BVZ) + Irinotecan (CPT-11) in Children with Recurrent Malignant Gliomas and Diffuse Brainstem Gliomas (PBTC-022) Tina Young Poussaint, United States
1:35 PM	471	Relationship between Early Perfusion Parameters Derived from DSC-MRI and Time-to-Progression in Patients with GBM following Anti-angiogenic Therapy Emma Essock-Burns, United States
1:45 PM	482	Diffusion-weighted Magnetic Resonance Imaging for the Evaluation of Tumor Progression in Patients Treated with Bevacizumab Kevin Becker, United States
1:55 PM	474	Long-term Clinical Monitoring of Gliomas Using Functional Diffusion Maps (FDMS) in Regions of Flair Abnormality Benjamin M. Ellingson, United States
2:05 PM	475	Evaluation of Cytotoxic and Anti-angiogenic Treatments Using Functional Diffusion Maps (FDMS) in Flair Abnormal Regions Benjamin M. Ellingson, United States
2:15 PM	479	Identifying Pseudoprogression in Glioblastoma: Utility of Conventional MR Findings Akash Shah, United States
2:25 PM	486	Molecular Image-guided Brain Tumor Resection with Miniature Dual-axis Confocal Microscopy Jonathan T.C. Liu, United States
2:35 PM	487	Kinetics of α-[C-11]Methyl-L-Tryptophan in Low-grade Brain Tumors: A Dynamic PET Study Csaba Juhasz, United States
2:45 PM		Grey Ribbon Crusade Al Musella
3:00 PM		Refreshment Break

3:15 – 5:00 PM Afternoon Concurrent Sessions

PEDIATRIC BASIC SCIENCE (Concurrent Session IV)

Moderators: Howard L. Weiner, Nalin Gupta

3:15 PM	71	Sonic Hedgehog: Hippo Pathway Cross-talk in Neural Precursor Proliferation and Pediatric Brain Tumorigenesis Anna Kenney, United States
3:25 PM	72	Atoh1 Collaborates with Gli1 to Induce Medulloblastoma by Regulating Hes Family Members Haotian Zhao, United States
3:35 PM	316	Pilot Study of Systemic and Intrathecal Chemotherapy followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors: A Pediatric Brain Tumor Consortium Trial Susan M. Blaney, United States
3:45 PM	337	Derailed Receptor Tyrosine Kinase Endocytosis in Glioblastoma: Sorting Nexin 3 Disrupts EGFR and MET Trafficking Promoting Cell Proliferation and Tumorigenicity Nada Jabado, Canada
3:55 PM	80	PI3 Kinase Mediated Deregulation of Actin Turnover by Slingshot 1 Phosphatase Impacts Cell Cycle Progression in Pediatric Ependymomas Timothy Van Meter, United States
4:05 PM	77	Sub-cellular Localization of Y-Box Protein 1 Regulates Proliferation, Invasion and Increased Mesenchymal Phenotype in Astrocytomas Nada Jabado, Canada
4:15 PM	335	Selective Induction of Optic Nerve Tumors by Notch3 Charles Eberhart, United States
4:25 PM	385	Universal Poor Survival in Children with Medulloblastoma Harboring Somatic TP53 Mutations Uri Tabori, Canada
4:35 PM	596	Risk Factors for Decreased Extent of Resection and Survival following Radical Resection of Craniopharyngiomas in Children Robert E. Elliott, United States

IMMUNOBIOLOGY AND IMMUNOTHERAPY (Concurrent Session V)

Moderators: Andrew T. Parsa, Linda M. Liau

3:15 PM	224	Gamma Interferon Mediated Superinduction of B7-H1 in PTEN Deficient Glioma Patients: An Immuno-resistant Phenotype that Can Confound Response to Cancer Vaccine Therapy Seunggu J. Han, United States
3:25 PM	222	Cellular Immunotherapy Trials Targeting Human Cytomegalovirus Antigens in Glioblastoma Duane A. Mitchell, United States
3:35 PM	230	Cancer Stem-like Cells from Glioblastoma Patients Mediate Immunosuppression that Is Reversed with Stat-3 Blockade Jun Wei, United States
3:45 PM	216	Recognition and Killing of Brain Tumor Stem Cells by CD8+ Cytolytic T Cells Christine Brown, United States
3:55 PM	206	Elevated P-STAT-3 Expression in Peripheral Blood Mononuclear Cells in Glioma Patients William E. Humphries, United States
4:05 PM	226	In Vivo Formation of Antigen-specific Immunological Synapses between Anti-tumor T Cells and Target Glioma Cells: A Detailed Quantitative and Qualitative Characterization of the Kinetics, Distribution and Microanatomy of the Anti-tumor Immune Response Pedro R. Lowenstein, United States

4:15 PM	231	A Pivotal Role of Type-1 Interferon Signaling in Immunosurveillance against Glioma: Mouse Studies Leading to Discovery of Novel Prognostic Markers in Humans Mitsugu Fujita, United States
4:25 PM	236	Immunotherapy of Malignant Brain Tumors Requires Antibody Response Katherine A. Murphy, United States
4:35 PM	219	B Cells Presentation of Tumor Antigen Is Required for Therapeutic Efficacy of an Immunotherapeutic Approach that Combines Immune-stimulatory and Conditional Cytotoxic Adenoviral Vectors for Glioblastoma Marianela Candolfi, United States

RADIATION ONCOLOGY (Concurrent Session VI)

Moderators: Minesh P. Mehta, Michael A. Vogelbaum

3:15 PM	465	Selective Sensitization of Epidermal Growth Factor Receptor Over-expressing Glioblastoma Cells To Ionizing Radiation by Inhibition of DNA Repair Kimberly Ng, United States
3:25 PM	439	Phase II Trial of Conventional Radiotherapy with Stereotactic Radiosurgery to High Risk Tumor Regions as Determined by MR Spectroscopy in Patients with Glioblastoma Multiforme Douglas B. Einstein, United States
3:35 PM	445	The Implications of Identifying Additional Cerebral Metastases during Stereotactic Radiosurgery Veronica Chiang, United States
3:45 PM	449	A Phase I Study of AT-101 plus Radiotherapy and Temozolomide and AT-101 plus Adjuvant Temozolomide for Patients with Newly Diagnosed Glioblastoma Multiforme John Fiveash, United States
3:55 PM	464	A New in Vitro Assay Using Gamma Knife Radiosurgery on Cells from Primary and Recurrent GBMS To Detect the Development of Radiation Resistance in Recurrent Tumors Kris A. Smith, United States
4:05 PM	426	A Phase I Trial of Dose per Fraction Escalation of Hypofractionated IMRT with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma Multiforme Changhu Chen, United States
4:15 PM	454	Multi-parameter Functional MR Imaging as an Early Biomarker of Tumor Response to Whole Brain Radiation in Brain Metastases Yue Cao, United States
4:25 PM	422	The Effects of Glycemic Control on Volumetric White Matter Changes after Whole Brain Radiation Nicholas J. Szerlip, United States
4:35 PM	424	Prognostic Factors and Outcomes of Patients Treated with Re-irradiation for Recurrent Glioblastoma Christopher E. Pelloski, United States
5:00 PM		Update on RANO Michael A. Vogelbaum
5:15 PM		Poster Viewing
6:15 PM		Poster Discussion
7:30 PM		Reception
7:30 PM		Young Investigators' Reception

7:00 – 8:00 AM

SUNRISE SESSIONS – MEET THE EXPERTS

Epidemiology and Pharmacogenomics	Leader: Melissa L. Bondy
Immunotherapy: Current Status of Clinical Trials	Leader: Roberta P. Glick
Medulloblastoma: Current State of Biology and Therapy	Leader: Daniel W. Fults
–omics and Brain Tumors: Genomics, Proteomics, Metabolomics, Ubiquinomics	Leader: Russell O. Pieper

8:00 AM – 12:00 PM

MORNING PLENARY SESSION

8:00 AM	Introduction of Hassenbush Lecturer: Katie O. Orrico, JD Frederick F. Lang
8:10 AM	Hassenbush Lecture Katie O. Orrico, JD

Plenary Session IV: Genomics and Proteomics

Moderators: Erwin Van Meir, Robert Jenkins

8:30 AM	192	IDH1 and IDH2 Mutations Play a Fundamental Role in Glioma Development Hai Yan, United States
8:40 AM	167	A Micro-RNA Expression Signature Accurately Discriminates Glioblastoma from Anaplastic Astrocytoma Kumar Somasundaran, India
8:50 AM	178	Identification of Prognostic Gene Signatures of Glioblastoma Based on the Cancer Genome Atlas Analysis Yong-Wan Kim, United States
9:00 AM	202	Abnormalities of the MAPK Pathway in Pediatric Low-grade Gliomas David Ellison, United States
9:10 AM	187	Model of a Cooperative Genetic Landscape in Gliomas Markus Bredel, United States
9:20 AM	193	Identification of CDK6 Oncogene Amplification, 10Q Deletion, and 17Q Gain as Novel Molecular Markers for Adverse Prognosis in Adult Medulloblastoma Stefan Pfister, Germany
9:30 AM	171	Micro-RNA-128 (MIRNA-128; CHR 2Q21.3) Down-regulation Targets BMI-1-Mediated Polycomb Silencing and Transcription Factor E2F3A, Key Regulators of Cell Cycle Progression Walter J. Lukiw, United States
9:40 AM	182	Micro-RNA-10A Is Highly Expressed in Glioblastoma Multiforme and May Contribute to its Malignant Behavior by Regulating HOXD10 Arti B. Gaur, United States
9:50 AM	188	Monosomy 10 Dysregulates EGFR Signaling in Glioblastomas Markus Bredel, United States
10:00 AM		Coffee Break

Plenary Session V: Stem Cells

Moderators: Jeremy N. Rich, Howard Colman

10:15 AM	499	CD133 Cells in Glioblastomas Are Multipotential and Generate Tumor Endothelium Viviane S. Tabar, United States
10:25 AM	517	Radial Glia Are Susceptible to Transformation into Ependymoma by Candidate Human Ependymoma Tumor Suppressor Genes (TSG) and Oncogenes Robert A. Johnson, United States
10:35 AM	509	Oncogenic EGF Receptor Variant Expressed in CNS Tumor Stem Cells Can Be Utilized for Targeted Cancer Stem Cell Therapy Siddhartha S. Mitra, United States
10:45 AM	513	EGFR Signaling Controls the Chromatin Binding Status of BMI1 Through A CK2/PP2A Phosphorylation/Dephosphorylation Pathway and Affects Astrocytoma Proliferation and Neural Stem Cell Differentiation Karlyne M. Reilly, United States
10:55 AM	496	TRIM3, the Human Homolog of Drosophila Brat, Regulates Neural Differentiation, MYC Expression and May Control Glioma Stem Cells Properties Gang Chen, United States
11:05 AM	501	Tumor Initiation Is Independent of Differentiation in Glioblastoma Stem Cells Howard Colman, United States

Plenary Session VI: Pathology/Prognostic Markers

Moderators: Cameron Brennan, Kenneth D. Aldape

11:15 AM	356	IDH1 132 Mutation Is Strongly Associated with the Proneural Gene Expression Signature in High-grade Astrocytomas Samir Kharbanda, United States
11:25 AM	380	Innovative Molecular Risk Stratification of Pediatric Intracranial Ependymoma Based on DNA Copy-number Alterations and MRNA Expression of Candidate Genes Hendrik Witt, Germany
11:35 AM	382	Identification of SGK1 as a Novel Prognostic Marker for Disease Outcome in Medulloblastoma Dominik Sturm, Germany
11:45 AM	384	The Matricellular Protein Spondin-1 Is a Novel Angiogenic Mediator in Pediatric Brain Cancers Timothy Van Meter, United States
11:55 AM	371	Using 3D 1H-MR Spectroscopy for Meningioma Surgery: Integrated Biochemical Image Guidance and Determination of Biochemical Markers of Clinically Aggressive Tumors in Vivo that Provide a Resection Advantage Nina Z. Moore, United States
12:05 PM	366	Molecular Classification of Glioma and Development of a Prognostic Metagene Expression Signature Erik P. Sulman, United States
12:15 PM		Concluding Remarks
12:20 PM		Lunch and SNO Business Meeting
1:00 PM		Adjourn

REGISTER TODAY!

Registration is now available for the

2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors

October 22-24 in New Orleans, Louisiana.

Visit www.cns.org/snosot and register today!

For more information contact:

**Society for Neuro-Oncology and the
AANS/CNS Section on Tumors**

c/o Congress of Neurological Surgeons

10 N. Martingale Road, Suite 190

Schaumburg, Illinois 60173

E-mail: info@1cns.org

Phone: 847 240 2500

Toll Free: 877 517 1CNS